(NMRA) Neumora Therapeutics - Ratings and Ratios
Kappa Antagonist, Agitation Drug, NMDA Modulator, CK1d Inhibitor
Description: NMRA Neumora Therapeutics October 29, 2025
Neumora Therapeutics (NASDAQ: NMRA) is a clinical-stage biopharma focused on oral small-molecule therapies for central-nervous-system (CNS) disorders, including major depressive disorder (MDD), dementia-related agitation, schizophrenia, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other neurodegenerative conditions. Its lead asset, navacaprant (NMRA-140), is a once-daily kappa-opioid receptor antagonist currently in a pivotal Phase 3 trial for MDD, while NMRA-511 is in Phase 1 for agitation in Alzheimer’s disease.
Beyond the two clinical programs, Neumora maintains a preclinical pipeline targeting high-unmet-need CNS indications: NMRA-NMDA and NMRA-M4R for schizophrenia, NMRA-CK1d for ALS, NMRA-NLRP3 for broader neurodegeneration, and NMRA-GCase for Parkinson’s disease. The global antidepressant market is estimated at ≈ $15 billion in 2024 and growing at a 3–4 % CAGR, providing a sizable revenue runway should navacaprant achieve regulatory approval. As of the latest 10-Q (Q2 2024), the company reported cash and cash equivalents of roughly $45 million, giving it an estimated 12-month operating runway at current burn rates.
Given the historically high attrition rates in CNS drug development (≈ 80 % failure from Phase 1 to approval) and the aging U.S. population driving demand for neuropsychiatric therapies, NMRA’s focus on novel mechanisms could be a differentiator, but investors should monitor Phase 3 readouts and cash-flow sustainability closely. For a deeper dive into NMRA’s valuation metrics and peer comparisons, the ValueRay platform offers a concise, data-driven snapshot worth reviewing.
NMRA Stock Overview
| Market Cap in USD | 475m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2023-09-14 |
NMRA Stock Ratings
| Growth Rating | -72.5% |
| Fundamental | 32.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -78.8% |
| Analyst Rating | 3.50 of 5 |
NMRA Dividends
Currently no dividends paidNMRA Growth Ratios
| Growth Correlation 3m | 81.5% |
| Growth Correlation 12m | -33.5% |
| Growth Correlation 5y | -76.6% |
| CAGR 5y | -55.69% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.57 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.98 |
| Sharpe Ratio 12m | -0.03 |
| Alpha | -123.97 |
| Beta | 2.952 |
| Volatility | 145.74% |
| Current Volume | 1824.7k |
| Average Volume 20d | 584.1k |
| Stop Loss | 2.8 (-7%) |
| Signal | 0.84 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.87 (>2.0%) and ΔFCFTA -37.83pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.87 (>3.0%) and CFO -195.7m > Net Income -252.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 10.54 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (161.7m) change vs 12m ago 1.70% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.11 (EBITDA TTM -264.2m / Interest Expense TTM 41.2m) >= 6 (WARN >= 3) |
Altman Z'' -41.53
| (A) 0.90 = (Total Current Assets 222.9m - Total Current Liabilities 21.2m) / Total Assets 223.8m |
| (B) -4.77 = Retained Earnings (Balance) -1.07b / Total Assets 223.8m |
| warn (B) unusual magnitude: -4.77 — check mapping/units |
| (C) -0.67 = EBIT TTM -210.7m / Avg Total Assets 314.1m |
| (D) -26.08 = Book Value of Equity -1.07b / Total Liabilities 40.9m |
| Total Rating: -41.53 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.75
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -75.71% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 = 2.50 |
| 5. Debt/Ebitda 0.47 = 2.33 |
| 6. ROIC - WACC (= -98.05)% = -12.50 |
| 7. RoE -98.95% = -2.50 |
| 8. Revenue Trend data missing |
| 9. EPS Trend 58.42% = 2.92 |
What is the price of NMRA shares?
Over the past week, the price has changed by +11.90%, over one month by +64.48%, over three months by +82.42% and over the past year by -74.30%.
Is Neumora Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NMRA is around 2.34 USD . This means that NMRA is currently overvalued and has a potential downside of -22.26%.
Is NMRA a buy, sell or hold?
- Strong Buy: 1
- Buy: 2
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the NMRA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.2 | 171.4% |
| Analysts Target Price | 8.2 | 171.4% |
| ValueRay Target Price | 2.8 | -6.6% |
NMRA Fundamental Data Overview November 01, 2025
P/B = 1.5762
Beta = 2.952
Revenue TTM = 0.0 USD
EBIT TTM = -210.7m USD
EBITDA TTM = -264.2m USD
Long Term Debt = 19.5m USD (from longTermDebt, last quarter)
Short Term Debt = 171.0k USD (from shortTermDebt, last quarter)
Debt = 510.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -124.0m USD (from netDebt column, last quarter)
Enterprise Value = 257.4m USD (474.5m + Debt 510.0k - CCE 217.6m)
Interest Coverage Ratio = -5.11 (Ebit TTM -210.7m / Interest Expense TTM 41.2m)
FCF Yield = -75.71% (FCF TTM -194.9m / Enterprise Value 257.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 318.0k) / Revenue TTM)
Tobins Q-Ratio = 1.15 (Enterprise Value 257.4m / Total Assets 223.8m)
Interest Expense / Debt = 8087 % (Interest Expense 41.2m / Debt 510.0k)
Taxrate = -0.05% (negative due to tax credits) (25.0k / -52.7m)
NOPAT = -210.8m (EBIT -210.7m * (1 - -0.05%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 10.54 (Total Current Assets 222.9m / Total Current Liabilities 21.2m)
Debt / Equity = 0.00 (Debt 510.0k / totalStockholderEquity, last quarter 182.9m)
Debt / EBITDA = 0.47 (negative EBITDA) (Net Debt -124.0m / EBITDA -264.2m)
Debt / FCF = 0.64 (negative FCF - burning cash) (Net Debt -124.0m / FCF TTM -194.9m)
Total Stockholder Equity = 254.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -112.6% (out of range, set to none)
RoE = -98.95% (Net Income TTM -252.1m / Total Stockholder Equity 254.8m)
RoCE = -76.82% (EBIT -210.7m / Capital Employed (Equity 254.8m + L.T.Debt 19.5m))
RoIC = -81.18% (negative operating profit) (NOPAT -210.8m / Invested Capital 259.6m)
WACC = 16.87% (E(474.5m)/V(475.0m) * Re(16.89%) + (debt cost/tax rate unavailable))
Discount Rate = 16.89% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.90%
Fair Price DCF = unknown (Cash Flow -194.9m)
EPS Correlation: 58.42 | EPS CAGR: 12.74% | SUE: 1.29 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for NMRA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle